Angitia Biopharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of AGA2118 for the Treatment of Osteoporosis
04 nov. 2024 07h30 HE
|
Angitia Incorporated Limited
WOODLAND HILLS, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for...
A Race Against Blindness Grants $1 Million Supporting Axovia Therapeutics’ Planned Clinical Trial for Bardet-Biedl Syndrome (BBS)
30 oct. 2024 08h01 HE
|
A Race Against Blindness
A Race Against Blindness grants $1M to Axovia Therapeutics for a clinical trial targeting blindness and obesity in Bardet-Biedl Syndrome.
A Family’s Race To Treat Childhood Blindness: A Race Against Blindness Grants $1 Million to Bardet-Biedl Syndrome Research
30 oct. 2024 08h00 HE
|
A Race Against Blindness
Arizona Family’s Journey: A Race Against Blindness grants $1M to Bardet-Biedl Syndrome research, fueling hope and potential cures for childhood blindness.
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
16 sept. 2024 06h05 HE
|
Boehringer Ingelheim
Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] at week 52...
Le PIONeeR Project présentera pour la première fois les résultats de son étude clinique de phase Ib/IIa lors de l’ESMO 2024
12 sept. 2024 04h21 HE
|
The PIONeeR Project
Le PIONeeR Project présentera pour la première fois les résultats de son étude clinique de phase Ib/IIa lors de l’ESMO 2024 Le symposium présidentiel "Eyes to the future" sera l'occasion de présenter...
The PIONeeR Project to Present Late-Breaking Results from its Phase Ib/IIa umbrella study at the ESMO Congress 2024
12 sept. 2024 04h21 HE
|
The PIONeeR Project
The PIONeeR Project to Present Late-Breaking Results from its Phase Ib/IIa umbrella study at the ESMO Congress 2024 The Presidential Symposium "Eyes to the future" will feature the first-ever...
Study Finds Cylinder Digital Health Platform Significantly Improves Digestive Health Symptoms
10 sept. 2024 10h00 HE
|
Cylinder
Study Finds Cylinder Digital Health Platform Significantly Improves Digestive Health Symptoms
PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)
19 août 2024 08h00 HE
|
PharmaTher Holdings Ltd.
TORONTO, Aug. 19, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo...
Eclipse Life Sciences Initiates Phase 2 Study for Novel Ophthalmology Steroid Implant for Diabetic Macular Edema (DME)
12 août 2024 07h45 HE
|
Eclipse Life Sciences
RESEARCH TRIANGLE PARK, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Eclipse Life Sciences, Inc., a privately held clinical-stage biopharmaceutical company focused on the development of novel therapies...
AFS Introduces MycoThrive™ Lion's Mane: A Clinically Studied Ingredient for Cognitive Performance
13 juil. 2024 12h55 HE
|
Applied Food Sciences, Inc.
Kerrville, Texas, July 13, 2024 (GLOBE NEWSWIRE) -- Applied Food Sciences (AFS) is proud to announce the launch of MycoThrive™ Lion's Mane, a groundbreaking functional ingredient recently clinically...